Application of immune checkpoint inhibitors neoadjuvant therapy in liver transplantation for hepatocellular carcinoma

doi:10.3877/cma.j.issn.1674-0793.2026.02.010

Abstract

Abstract:

Immune checkpoint inhibitors (ICIs), as a major breakthrough in cancer immunotherapy, have demonstrated significant efficacy in the systemic treatment of hepatocellular carcinoma (HCC). In recent years, the application of neoadjuvant therapy with ICIs in liver transplantation for HCC has become a hot topic, aiming to reduce tumor burden and improve transplant outcomes through pre-operative immune activation. However, ICIs may exacerbate post-transplant immune rejection, and their safety and efficacy still require careful evaluation. Based on the latest domestic and international research progress, this article reviews the current status and key issues regarding the application of neoadjuvant therapy with ICIs in liver transplantation for HCC.

Key words: Immune checkpoint inhibitors, Neoadjuvant therapy, Liver neoplasma, Liver transplantation

Jianyong Liu, Yi Jiang. Application of immune checkpoint inhibitors neoadjuvant therapy in liver transplantation for hepatocellular carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2026, 20(02): 127-132.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2026.02.010

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2026/V20/I02/127

References 44

［1］	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71（3）: 209-249.
［2］	国际肝胆胰协会中国分会, 中华医学会外科学分会肝脏外科学组, 中国临床肿瘤学会（CSCO）肝癌专家委员会. 肝细胞癌免疫联合治疗多学科中国专家共识（2023版）[J]. 中华消化外科杂志, 2023, 22（3）: 293-315.
［3］	Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation[J]. Gut, 2002, 50（1）: 123-128.
［4］	中华医学会器官移植学分会, 中国医师协会器官移植医师分会肝移植学组, 中国康复医学会器官移植康复专业委员会. 中国肝癌肝移植受者免疫检查点抑制剂应用专家共识（2024版）[J]. 中华器官移植杂志, 2024, 45（7）: 415-431.
［5］	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7（1）: 6.
［6］	肖治宇, 陈亚进. 肝胆肿瘤新辅助治疗的模式及方案选择[J]. 中国实用外科杂志, 2023, 43（3）: 276-280.
［7］	Marino R, Hassan AT, Fagenson A, et al. Liver transplantation for hepatocellular carcinoma following immunotherapy[J]. Curr Opin Organ Transplant, 2025, 30（4）: 242-250.
［8］	Kittai AS, Oldham H, Cetnar J, et al. Immune checkpoint inhibitors in organ transplant patients[J]. J Immunother, 2017, 40（7）: 277-281.
［9］	国家卫生健康委员会医政司. 原发性肝癌诊疗指南（2024年版）[J/OL]. 中华普通外科学文献（电子版）, 2024, 18(6): 385-410.
［10］	Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76（3）: 681-693.
［11］	De Stefano N, Patrono D, Colli F, et al. Liver transplantation for hepatocellular carcinoma in the era of immune checkpoint inhibitors[J]. Cancers（Basel）, 2024, 16（13）: 2374.
［12］	Tabrizian P, Holzner ML, Ajmera V, et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study[J]. J Hepatol, 2025, 82（3）: 512-522.
［13］	Schwenk L, Rauchfuß F, Ali-Deeb A, et al. Individualized curative treatment for malignant diseases through liver transplantation[J]. Chirurgie（Heidelb）, 2024, 95（2）: 122-128.
［14］	Ortiz V, Loeuillard E. Rethinking immune check point inhibitors use in liver transplantation: implications and resistance[J]. Cell Mol Gastroenterol Hepatol, 2025, 19（1）: 101407.
［15］	Braun F, Schäfer JP, Dobbermann H, et al. Hepatocellular carcinoma[J]. Chirurgie（Heidelb）, 2022, 93（7）: 635-643.
［16］	Davis L, Casselbury MB, Wilson S. Checkpoint inhibitor therapy: immune-related adverse event management[J]. Nursing, 2024, 54（11）: 26-33.
［17］	Liu Z, Zhu Y, Xie H, et al. Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives[J]. Front Pharmacol, 2023, 9（13）: 1077468.
［18］	Mok K, Wu C, Chan S, et al. Clinical management of gastrointestinal and liver toxicities of immune checkpoint inhibitors[J]. Clin Colorectal Cancer, 2024, 23（1）: 4-13.
［19］	Triantafyllou E, Gudd CLC, Possamai LA. Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management[J]. Nat Rev Gastroenterol Hepatol, 2025, 22（2）: 112-126.
［20］	Werner W, Kuzminskaya M, Lurje I，et al. Overcoming resistance to immune checkpoint blockade in liver cancer with combination therapy: stronger together?[J]. Semin Liver Dis, 2024, 44（2）: 159‐179.
［21］	Trifylli EM, Koustas E, Papadopoulos N, et al. An insight into the novel immunotherapy and targeted therapeutic strategies for hepatocellular carcinoma and cholangiocarcinoma[J]. Life, 2022, 12（5）: 665.
［22］	Qiu S, Zong Z, He K. Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection[J]. Immunotherapy, 2025, 17（10）: 697-701.
［23］	Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period[J]. Transpl Immunol, 2021, 66: 101386.
［24］	Rezaee-Zavareh MS, Yeo YH, Wang T, et al. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis[J]. J Hepatol, 2025, 82（1）: 107-119.
［25］	Wassmer CH, El Hajji S, Papazarkadas X, et al. Immunotherapy and liver transplantation: A narrative review of basic and clinical data[J]. Cancers（Basel）, 2023, 15（18）: 4574.
［26］	Kuo FC, Chen CY, Lin NC, et al. Optimizing the safe washout period for liver transplantation following immune checkpoint inhibitors with atezolizumab，nivolumab，or pembrolizumab[J]. Transplant Proc, 2023, 55（4）: 878-883.
［27］	Tabrizian P, Yu A, Debnath N, et al. Immunotherapy and liver transplantation: the future or the failure?[J]. Surg Clin North Am, 2024, 104（1）: 163-182.
［28］	Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective[J]. J Hepatol, 2021, 75（5）: 1203-1216.
［29］	Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: risk factors，screening and clinical presentation[J]. World J Hepatol, 2019, 11（3）: 261-272.
［30］	Bodzin AS, Lunsford KE, Markovic D, et al. Predictingmortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266（1）: 118-125.
［31］	Ho CM, Chen HL, Hu RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: A review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 26（11）: 1758835919843463.
［32］	Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7（1）: 106.
［33］	Yao RR, Zhang QB, Ge MX, et al. The safety and efficacy of atezolizumab for recurrent primary liver cancer after liver transplantation[J]. Discov Oncol, 2025, 16（1）: 553.
［34］	Zhang P, Zhu G, Li L, et al. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature[J]. Transplant Rev（Orlando）, 2022，36（4）: 100712.
［35］	Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after Nivolumab treatment-A case report with systematic literature research[J]. Transplant Direct, 2018, 4（8）: e376.
［36］	Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: A case series and systematic review of literature[J]. Oncologist，2020, 25（6）: 505-514.
［37］	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated，PD-L1-positive，advanced non-small-cell lung cancer（KEYNOTE-010）: A randomised controlled trial[J]. Lancet, 2016, 387（10027）: 1540-1550.
［38］	Agrawal S, Feng Y, Roy A, et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy[J]. J Immunother Cancer, 2016, 15（4）: 72-82.
［39］	Mardomi A, Mohammadi N, Khosroshahi HT, et al. An update on potentials and promises of T cell co-signaling molecules in transplantation[J]. J Cell Physiol, 2020, 235（5）: 4183-4197.
［40］	Abdelrahim M, Esmail A, Saharia A, et al. Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view[J]. Cancers（Basel）, 2022, 14（7）: 1760.
［41］	Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma[J]. Pediatr Blood Cancer, 2017, 64（12）: 26682.
［42］	Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6（7）: 970-973.
［43］	Xie M, Dang ZP, Sun XG, et al. An analysis report on the application of immune checkpoint inhibitors after liver transplantation[J]. Ther Adv Chronic Dis, 2022, 19（13）: 20406223221099334.
［44］	Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma[J]. J Hepatol, 2023, 79（2）: 506-515.

[1]	Breast Disease Branch of Shenzhen Medical Association, Tumor Branch of Shenzhen Medical Association, Breast Specialist Physicians Branch of Shenzhen Medical Doctor Association, Breast Health and Rehabilitation Management Committee of Shenzhen Health Management Association, Breast Cancer Committee of Shenzhen Anti-Cancer Association, Tumor Radiation Therapy Committee of Shenzhen Anti-Cancer Association, Thyroid and Breast Diseases Committee of Shenzhen Integrated Traditional Chinese and Western Medicine Association. Expert consensus on efficacy prediction and evaluation of neoadjuvant therapy for breast cancer （2025 edition） [J]. Chinese Journal of Breast Disease(Electronic Edition), 2025, 19(06): 321-330.
[2]	Long Dong, Yonghong Dong. Research progress on the role of melatonin in malignant tumors of the digestive system [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(06): 408-413.
[3]	Jiale Gao, Zhongtao Zhang. Latest advances and hotspots in the field of colorectal cancer surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 595-599.
[4]	Branch of Organ Transplantation of Chinese Medical Association. Chinese expert consensus on prevention and treatment of recurrence and metastasis after liver transplantation for hepatocellular carcinoma (2025 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2025, 19(06): 385-397.
[5]	Junjie Li, Pei Dong, Cheng Yao, Ze Liu, Yong Li. Advances in immunotherapy for prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2026, 20(02): 209-215.
[6]	Xuanyi Zhu, Yiteng Zhao, Lianxin Liu, Zebin Zhu, Shugeng Zhang. Current status and advances in key technologies of hybrid laparoscopic liver transplantation [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2026, 19(01): 56-59.
[7]	·Maimaiti Maiwulanjiang, ·Tulading Aliya, ·Tuxun Tuerhongjiang. Immunosuppression strategy for ABO-incompatible liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(02): 152-159.
[8]	Xiaozhen Wang, Canhui Chen, Shanhua Tang, Haojia Dai, Yangge Feng, Kai Wang, Qingping Li, Chuanjiang Li. Construction and efficiency comparison of prediction models based on different machine learning technologies for early severe complications after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(02): 197-204.
[9]	Pengfei Yin, Kun Wu, Huaizhi Wang, Lei Cai. Advances in immunotherapy strategy for hepatocellular carcinoma and its application in perioperative period [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(01): 21-27.
[10]	Haoran Wang, Xinyuan Liu, Hua Fan. Application of ICG fluorescence imaging in perfusion and functional evaluation of liver graft [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(06): 912-918.
[11]	Lina Chang, Nannan Liu. Predictive value of DWI combined with DCE-MRI quantitative parameters for pCR after neoadjuvant therapy for locally progressive rectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2026, 16(02): 125-129.
[12]	Bin Hu, Lin Liu. Correlation between dynamic changes in CT imaging features after neoadjuvant therapy and postoperative pathologic complete response rate in esophageal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(06): 627-634.
[13]	Yuhan Hou, Fujin Jiang, Sugui Wang. Progress in immunotherapy of bladder cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(06): 471-475.
[14]	Xiao Shen, Haitao Yan, Jinxing Zhang, Qingquan Zu, Sheng Liu, Haibin Shi. MRI-Based Radiomics for Predicting Treatment Response to TACE Combined with Molecular-Targeted Agents and Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2026, 14(01): 72-80.
[15]	Editorial Office of Chinese Journal of Thoracic Surgery (Electronic Edition). Da Vinci elite surgeons online seminar series (session two): robotic pulmonary surgery after neoadjuvant immunotherapy [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2026, 13(01): 91-94.

Please choose a citation manager

Content to export